Best Life Sciences Companies in Melbourne, Australia

Mesoblast specializes in developing cellular medicines. The company has a clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. These clinical programs target therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The Japanese Government has approved TEMCELL® HS. Inj., a product based on their proprietary allogeneic mesenchymal lineage adult stem cell technology licensed to JCR Pharmaceuticals Co. Ltd for the treatment of graft versus host disease in children and adults in Japan. Their product candidate, MSC-100-IV, has orphan drug designation and is being developed under an accelerated regulatory approval pathway in line with the United States Food and Drug Administration (FDA) discussions for children with steroid-refractory acute graft versus host disease. Two other lead product candidates, MPC-150-IM and MPC-06-ID, are in late-stage development in Phase 3 programs targeting, respectively, advanced chronic heart failure and chronic low bac

Developer of AI-powered CT imaging solutions. The company is developing AI-based weight-bearing CT (WBCT) imaging systems for the orthopedic and musculoskeletal (MSK) specialties for the diagnosis of lower extremity conditions.

Funding rounds

• Feb 2026Post IPO$2.8M
• Feb 2023Series A$25M
• Nov 2022Seed$255.4K

Founders & team

Arun SinghCEO

Investors

Tenmile, Firetrail, Karst Peak Capital, Ilwella

Tech stack

Amazon SesAmazon Web ServicesAnimate.CssAutoptimizeCalendlyClickdimensions

{}

Funding rounds

• Oct 2025Series B$22.4M
• Feb 2025Series B$5M
• Jun 2021Series B$25M

Founders & team

Christophe DemaisonManaging Director

Investors

Uniseed, Minderoo Foundation, Brandon Capital, Flu Lab, Gates, Stoic Venture Capital

Developer of therapeutics for respiratory diseases. These therapies help in modulating the receptor for advanced glycation end-products (RAGE), which is a multi-ligand, transmembrane receptor expressed in the lung. The RAGE is recognized as a mediator of pathological, chronic lung inflammation and has been involved in the lung diseases such as severe asthma, chronic obstructive pulmonary disease, cystic fibrosis, and acute respiratory distress syndrome.

Provider of therapies to treat neurodegenerative disease. The company's drugs include PBT434 is meant for Parkinsonian disorders and is being evaluated in clinical trials. The drug is a small molecule designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain.

Funding rounds

• Sep 2025Post IPO$13.1M
• Feb 2021Grant (prize money)$495K
• May 2008Post IPO$6.7M
• Post IPO—

Founders & team

David StamlerChief Executive Officer

Investors

The Michael J. Fox Foundation

Developer of therapeutics for neurodegenerative diseases. The pipeline includes NUZ-001S-Monepante which targets and address the underlying mechanisms of neurodegenerative disease and treat Amyotrophic lateral sclerosis.

Funding rounds

• Feb 2026Post IPO$3.6M

Founders & team

Michael ThurnCEO & Managing Director

Investors

Obsidiangp

Tech stack

Animate.CssAnime.JsBackbone.JsCloudflareFancyboxFont Awesome

PolyActiva has developed a platform technology for slow-release, site-specific drug delivery. Upon the application of the treatment, complete erosion of the implant occurs leaving no residue following drug release. This technology can be used to produce new biomedical products, drug-delivery devices and device components that enable delivery of drugs directly to the affected organ or treatment site. They are produced from a proprietary drug-polymer conjugate technology. Products are being developed for glaucoma, endophthalmitis, and osteoarthritis.

Developer of a platform for personalized chemotherapy dosing using body analysis. The platform analyzes CT scans to segment muscle, fat, bone, and tumor volume. This creates a detailed body composition profile for each patient. Machine learning models then predict the optimal chemotherapy dose before the first cycle.

Funding rounds

• Oct 2025Seed$1.6M

Founders & team

Justin YeungCo-Founder & CMOAbhijeet WaykarCo-Founder & CEO & CTO

Incannex is a clinical stage pharmaceutical company that specializes in the development of medicinal cannabinoid compounds and psychedelic therapies. They have a diversified portfolio of 28 FDA compliant R&D programs and are well positioned as a leader in the development of novel cannabinoid pharmaceuticals and psychedelic therapies.

Funding rounds

• Mar 2025Post IPO$12.5M

Founders & team

Joel LathamCEO & MD

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Provider of software to manufacturers and labs custom-fit businesses. The company offer products such as dental autodesign, audio autodesign, and smartphone scanning. It allows manufacturers to create custom-fit hearing devices without needing impression material or expensive 3D scanning technology.

Funding rounds

• Sep 2025Series A$5.8M
• Aug 2021Seed$1M
• Grant (prize money)$200K

Founders & team

Phil KinsellaFounder & CTO

Investors

Significant, Starfish Ventures, Australian Government, Co:Act, Swinburne University of Technology, AfterWork Ventures

Tech stack

Amazon Web ServicesApple Icloud MailCloudflareCloudflare Bot ManagementCore-JsGoogle Analytics

Kinoxis Therapeutics is involved in the development of a range of therapeutic compounds for treating CNS disorders in collaboration with the University of Sydney. They are more focused on developing antiaddiction drugs, illicit, and prescription drugs. Their lead compound, SOC-1, which is an anti-addiction drug. It mimics the properties of the oxytocin hormone.

Funding rounds

• Aug 2024Series B$9.6M
• Sep 2019Grant (prize money)$4.6M
• Feb 2018Series A$3.9M

Founders & team

Hugh AlsopCo-Founder & CEOMichael BowenCo-Founder & CSO

Investors

Uniseed, UniSuper, Stoic Venture Capital, Avicella Capital, University of Sydney, NIH

Developer of vaccine for peanut allergy. It offers a lead candidat PVX108 that consist of selected fragments of peanut proteins that don’t contain the parts of the nut proteins which cause the life-threatening anaphylaxis reactions and turn off their allergic reactions.